Figure 2.
(A) Percentage of subjects (95% CI) with seroresponse and percentage of subjects (95% CI) with hSBA titers ≥8 against serogroups ACWY at one month after first dose (Day 31) and 1 month after the second dose (Day 91), by vaccination group. (B) hSBA geometric mean titers (95% CI) against serogroups ACWY at baseline (Day 1) and one month after the first and second doses, by vaccination group.